A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.

doi:10.1016/j.jtha.2023.02.019

Article

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.

Journal of thrombosis and haemostasis : JTH - 1 Jun 2023

Strijbis Viola J F, Romano Lorenzo G R, Cheung Ka Lei, Eikenboom Jeroen, Liu Ying Poi, McCreary Andrew C, Leebeek Frank W G, Bos Mettine H A

Abstract excerpt

BACKGROUND: Recombinant factor (F)IX-FIAV has previously been shown to function independently of activated FVIII (FVIIIa) and ameliorate the hemophilia A (HA) phenotype in vitro and in vivo. OBJECTIVES: The aim of this study was to assess the efficacy of FIX-FIAV in plasma from HA patients using thrombin generation (TG) and intrinsic clotting activity (activated partial thromboplastin time [APTT]) analyses....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.

Abstract excerpt

Topics

Related research